Lexaria Bioscience shares are trading higher after the company announced it completed its HOR-A22-1 study that showed significant enhancement in the oral delivery of the estrogen hormone estradiol.
Portfolio Pulse from Benzinga Newsdesk
Lexaria Bioscience announced the completion of its HOR-A22-1 study, which demonstrated a significant enhancement in the oral delivery of the estrogen hormone estradiol. This news has led to an increase in the company's share price.

May 18, 2023 | 7:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lexaria Bioscience's shares are trading higher after the successful completion of the HOR-A22-1 study, which improved the oral delivery of estradiol.
The successful completion of the HOR-A22-1 study indicates a potential improvement in Lexaria Bioscience's product offerings. This positive news has led to an increase in the company's share price, making it likely to continue in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100